<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Approximately 1000 patients who have suffered a well-documented <z:hpo ids='HP_0001727'>thromboembolic stroke</z:hpo> within two weeks to four months of study entry will be enrolled in this double-blind, randomized, placebo controlled, parallel group trial </plain></SENT>
<SENT sid="1" pm="."><plain>Five Canadian and five United States study centers will participate </plain></SENT>
<SENT sid="2" pm="."><plain>The enrollment period will be two and one half years, and follow-up will run for an additional six months to a common termination point at three years </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="9589">Ticlopidine hydrochloride</z:chebi>, administered as two 125 mg tablets b.i.d </plain></SENT>
<SENT sid="4" pm="."><plain>(500 mg/day total dose) will be compared with placebo for efficacy in the prevention of recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, and overall mortality </plain></SENT>
<SENT sid="5" pm="."><plain>Inclusion and exclusion criteria will be the minimum necessary to provide safety and scientific validity </plain></SENT>
<SENT sid="6" pm="."><plain>After a screening visit, qualifying patients will be randomly assigned to <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> or placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Follow-up laboratory studies for monitoring complete blood and platelet counts will be made at weeks 2, 4, 6, 8, 10 and 12, and then months 4, 5, 6, 8 and then every 4 months thereafter </plain></SENT>
<SENT sid="8" pm="."><plain>Follow-up clinic visits will be made at 1 month, 4 months, and then every four months thereafter for clinical evaluation and for dispensing test medication </plain></SENT>
<SENT sid="9" pm="."><plain>Study outcome events will be appropriately documented on case report forms </plain></SENT>
<SENT sid="10" pm="."><plain>The statistical analysis will evaluate the initial comparability of the two treatment groups, and the principal outcomes of the two groups will be compared by using the Mantel-Haenszel life table analysis </plain></SENT>
</text></document>